News

Higher dietary fiber intake among myocardial infarction (MI) survivors lowers the risk of subsequent all cause and cardiovascular mortality, according to a prospective study published April 29 in BMJ.

The sale of electronic or e-cigarettes may soon be regulated by FDA. Last week the agency proposed a new rule that would extend its authority to cover additional tobacco products, including e-cigarettes.

An FDA advisory panel recommended against Merck’s attempt to sell its prescription drug, montelukast sodium (Singulair), as an over-the-counter product for allergy relief in adults only.

FDA approved ceritinib (Zykadia, Novartis) for patients with metastatic non-small cell lung cancer (NSCLC).

RightCare’s software, based on 10 years of academic and clinical research, has been proven to reduce readmission rates by as much as 35%.

The increase in recent acquisition activity among Big Pharma illustrates different growth strategies, according to industry watchers.

Preventable deaths with in the top 5 causes of death vary across states, and CDC notes an opportunity to improve

Lorazepam is not necessarily better at stopping epileptic seizures in children than diazepam, according to a new study published in the April 30 issue of JAMA.

FDA approved siltuximab (Sylvant, Janssen Biotech) to treat patients with multicentric Castleman’s disease (MCD), a rare disorder similar to lymphoma.

Pharmacists can play an influential role in ensuring patient access to quality health care by both encouraging and enhancing patient medication adherence and increasing patient knowledge of their disease states and medication therapies.

FDA approved umeclidinium (Incruse Ellipta, GlaxoSmithKline) once-daily anticholinergic for long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

Assessing the clinical utility of diagnostic testing has always been a complicated undertaking. And as new genetic tests enter the equation, that complexity will only increase. To examine the issues surrounding clinical utility, I’d like to share a quick story.

Even if Medicare doesn't reimburse physicians for consultations, patients still want to talk about their care preferences

A dearth of informatics to confirm the intuitive benefits of wellness makes it difficult for a numbers-driven health insurance system to know how to invest its resources

Behind the political issues and the deep emotions is the reality that the United States must overhaul end-of-life care

States with all-payer claims databases and user-friendly websites earned Bs and Cs

Continuity of care cuts Medicare costs

Experts say directly comparing ACO models can be difficult because stakeholders often take different approaches to care management

More than 150 million now using the services

Rather than a big medical record in the sky a community is sharing information via a non-profit, public-private collaborative

Move from volume to value by fundamentally challenging the status quo

How quality programs for providers can be beneficial in an accountable care setting

Optimize benefit plans to motivate patients to take advantage of cost-effective drugs

FDA is holding a public workshop on its proposed prescription drug tracking system on May 8-9.

Patients who use statins are consuming more calories and fats than a decade earlier, increasing the risk of obesity, diabetes, and cardiovascular disease, according to a study published online in JAMA Internal Medicine.

Poor communication between care providers that leads to care gaps and medical errors is a serious problem within the healthcare system, but so is patient behavior outside the physician’s office

Pfizer said it offered to buy AstraZeneca for approximately $100 billion. If the deal materializes, it would represent the biggest-ever foreign takeover of a British business and allow Pfizer to pay a lower corporate tax rate of 20%, according to some reports.

The biggest challenge in tackling opioid abuse is lack of awareness and understanding of addictive diseases generally and specifically opioid use disorders, as well as misinformation and negative perceptions of medication-assisted therapies (MATs), according to a recent opinion article published in the New England Journal of Medicine.

Pharmacists who contacted high-risk patients within 72 hours of discharge from Massachusetts General Hospital, Boston, found more than half of the patients had medication-related issues. In a different group of high-risk patients who had received inpatient interventions, 35% of patients were found to have issues after a pharmacist reviewed their medications just prior to discharge, according to Laura Carr, PharmD.

Pharmacist-led care with prescribing authority substantially improved risk factors at 6 months among stroke survivors than nurse case managers who monitored patients and provided feedback to their primary care physicians, according to a report published in the Canadian Medical Association’s journal, CMAJ.